Guardant Health, Inc. Stock News

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health's common stock (the “common stock offering”). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an additional $37...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified institutional buyers pursuant t...

Guardant Health, Inc.'s Shield ADLT reimbursement, Quest, and guidance raise show good adoption momentum. These positives keep me bullish on GH stock. Their oncology business remains the revenue anchor. Biopharma & Data also came in with good margins and provided some diversification. GH's recent Q3 report showed growing revenues, more Shield tests, and, ex-Screening, they became cash flow posi...

The cancer-focused biotech surprised on the upside for both revenue and profitability in its latest reported quarter. Revenue rose by almost 40% year over year in that period.

Guardant Health delivered extremely robust Q3 results and raised full-year guidance, with Reveal and Shield beginning to make material contributions. Guardant's therapy selection and biopharma businesses also remain strong. While GH is burning cash, this is in support of the screening business' rapid expansion. The company is now on a clear path to breakeven in the next few years.

Guardant's oncology and screening businesses are expanding at a rapid pace. New partnerships should drive further gains.

Guardant Health, Inc. ( GH ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman AmirAli Talasaz - Co-CEO & Director Michael Bell - Chief Financial Officer Conference Call Participants Bradley Bowers - Mizuho Securities USA LLC, Research Division Douglas Schenkel - Wolfe Rese...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%, driven by: Oncolo...